Excitation-Dependent Theranostic Nanosheet for Cancer Treatment.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29430871.
- Also identified by DOI 10.1002/adhm.201701123.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this work, a novel ruthenium complex loaded monolayer layered double hydroxide (LDH) (denoted as Ru(C-bpy)<sub>2</sub> /mLDH) as supramolecular nanosensor is synthesized, which is greatly exclusive to the hypoxic tumor microenvironment. The Ru(C-bpy)<sub>2</sub> /mLDH ultrathin sheet displays not only enhanced luminescence lifetime compared to the parent Ru(C-bpy)<sub>2</sub> alone, but also improved oxygen responsibility under an excitation of 488 or 800 nm. Moreover, the Ru(C-bpy)<sub>2</sub> /mLDH is possessed of two-photon fluorescence imaging ability under the 800 nm irradiation. In addition, the Ru(C-bpy)<sub>2</sub> /mLDH can generate singlet oxygen with a high yield (φ<sub>∆</sub> ) of 0.28 under the 520 nm irradiation, while the φ<sub>∆</sub> of Ru(C-bpy)<sub>2</sub> is 0.19. Therefore, the Ru(C-bpy)<sub>2</sub> /mLDH can be applied as a supramolecular theranostic agent with light-switchable cancer imaging and photodynamic therapy properties.
Medical subject headings
- Nanostructures
- Neoplasms, Experimental
- Photochemotherapy
- Ruthenium Compounds
- Theranostic Nanomedicine
- Tumor Hypoxia
- Tumor Microenvironment